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SUMMARY
Innate immune memory is the phenomenon whereby
innate immune cells such as monocytes or macro-
phages undergo functional reprogramming after
exposure to microbial components such as lipopoly-
saccharide (LPS). We apply an integrated epige-
nomic approach to characterize the molecular events
involved in LPS-induced tolerance in a time-depen-
dent manner. Mechanistically, LPS-treated mono-
cytes fail to accumulate active histone marks at
promoter and enhancers of genes in the lipid meta-
bolism and phagocytic pathways. Transcriptional
inactivity in response to a second LPS exposure in to-
lerizedmacrophages is accompanied by failure to de-
posit active histone marks at promoters of tolerized
genes. In contrast, b-glucan partially reverses the
LPS-induced tolerance in vitro. Importantly, ex vivo
b-glucan treatment of monocytes from volunteers
with experimental endotoxemia re-instates their ca-
pacity for cytokine production. Tolerance is reversed
at the level of distal element histone modification
and transcriptional reactivation of otherwise unre-
sponsive genes.
INTRODUCTION
Accumulating evidence suggests thatmonocytes can be reprog-
rammed by exposure to microbe-associated molecular patterns
(MAMPs) during their time in the circulation (Quintin et al., 2014).
In this model, immune tolerance in myeloid cells, be they mono-
cytes in the circulation or macrophages in the tissues (lipopoly-
saccharide macrophages [LPS-Mfs]), represents one extreme
in the spectrum of innate immune memory and can be induced
by high bacterial burden in vivo or lipopolysaccharide (LPS)
exposure in vitro (Netea et al., 2016). On the other hand, trained
immunity can be induced by exposure to certain vaccines,
microbial components, or metabolites, and is a state character-
ized by increased pro-inflammatory response to secondary un-
related infections (Netea et al., 2016). We recently showed that
tolerance (induced by LPS) and trained immunity (induced by
Candida albicans b-glucan [BG]) are both associated with spe-
cific epigenomic states (Cheng et al., 2014; Saeed et al., 2014).
Most notably, the identity of these macrophage subtypes was
specified by differences in primed and active distal element rep-
ertoires (Saeed et al., 2014).
Monocytes and macrophages play an important role in the
pathophysiology of sepsis and inflammation, along with other
innate and adaptive immune cells (Biswas and Lopez-Collazo,
2009). Transcriptome analysis of tolerant monocytes from
sepsis patients (Shalova et al., 2015) and a mouse sepsis model
(Foster et al., 2007) reveals that the tolerized phenotype cannot
be explained purely through failure of specific signaling path-
ways induced by pattern recognition receptors to activate
downstream genes. This implicates a role for local chromatin
architecture and specific transcriptional regulators in control-
ling the expression of tolerized genes (Glass and Natoli,
2016). Further, studies in human cancers have revealed com-
monalities between inflammation and cancer associated toler-
ance, including the role for IDO1 in both (Bessede et al.,
2014). Accordingly, several anti-cancer drugs, such as bromo-
domain and extraterminal domain family (BET) inhibitors and a
topoisomerase inhibitor, have proven efficacious in blocking
inflammation-associated death in mice (Nicodeme et al.,
2010; Rialdi et al., 2016). The specific epigenetic and transcrip-
tional remodeling induced by the initial LPS exposure and the
extent to which it specifies tolerance to future LPS exposure
are unknown.
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Figure 1. Epigenomic and Transcriptomic Remodeling of Monocytes Induced by Exposure to LPS or BG
(A) Experimental setup for epigenomic interrogation of monocyte-to-macrophage differentiation and induction of tolerance (with LPS) or trained immunity (with BG).
(B) PCA plots of H3K27ac and H3K4me1 dynamic enhancers (monocytes, red circle; naive, circle; LPS, triangle; BG, square; 1 hr, blue; 4 hr, black; day 1, green;
and day 6, brown). Dynamic H3K27ac patterns show a clear deviation from the differentiation pathway (PC1) in LPS-treated cells. On the other hand, BG-treated
cells at day 1 are well on their way toward a full macrophage epigenetic profile.
(legend continued on next page)
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Here, as part of the BLUEPRINT epigenome consortium (http://
www.blueprint-epigenome.eu), we report the time-resolved,
comprehensive epigenomes of human monocyte-to-macro-
phage differentiation and induction of tolerance with LPS and
training with BG. Our epigenomic analysis revealed that tolerance
and trained immunity involve opposing regulation of common
pathways during early exposure to MAMPs, leading to distinct
epigenomic states in the two macrophage subtypes. We there-
fore hypothesized that BG may be capable of reversing LPS-
induced tolerance. We show that ex vivo BG exposure can rein-
state a responsive phenotype in both monocytes tolerized by
ex vivo LPS exposure and monocytes tolerized by in vivo exper-
imental endotoxemia in healthy volunteers. This reversal of toler-
ance involves epigenomic reprogramming of macrophages.
RESULTS
Distinct Temporal Epigenetic Remodeling in Response
to Microbial Components
Two innate immune memory states can be induced in culture
through an initial exposure of primary humanmonocytes to either
LPS or BG for 24 hr, followed by removal of stimulus and differ-
entiation to macrophages for an additional 5 days (Figures 1A
and S1; Quintin et al., 2012; Saeed et al., 2014). The three sub-
types of macrophages generated in this study were untreated
naive macrophages (naive-Mfs), LPS-exposed tolerized macro-
phages (LPS-Mfs), and BG-exposed trained macrophages (BG-
Mfs). To gain insight into the mechanisms and order of events
that ultimately lead to these three subtypes, we generated epi-
genomic data at several time points during this process (two do-
nors; summarized in Table S1 and Figure S1; GEO: GSE85246).
Depending on the modification, 2%–31% of marked regions
showed dynamics during differentiation or LPS or BG exposure,
with H3K27ac at promoters and enhancers being the most dy-
namic mark in number and range (Figure S1; Table S1). Interest-
ingly, epigenetic changes were observable as early as 1 hr in
response to LPS and 4 hr to BG (Figure 1B). The overall
H3K27ac pattern at dynamic promoters and enhancers indicates
that the most pronounced changes are associated with differen-
tiation (principal component 1 [PC1]), with BG- and RPMI-
treated monocytes partially establishing macrophage-specific
active regions already by day 1 (Figure 1B). Conversely, LPS
treatment results in establishment of pro-inflammatory associ-
ated active elements (PC2) and stunted differentiation, followed
by partial ‘‘catch up’’ establishment of differentiation marks
following removal of stimulus (Figures 1B and S1). Contrary to
this catch up of H3K27ac marked enhancers, the H3K4me1
marked enhancer repertoire of LPS-Mfs is significantly different
from those of naive-Mfs and BG-Mfs (Figure 1B). Repressive
marks, H3K9me3 and H3K27me3, showed no dynamics during
the first 24 hr, indicating little role in the early, priming phase of
innate immune memory (Figure S1C; Table S1).
In total, 17,500 enhancers with dynamic H3K27ac were identi-
fied (Figure S1B). The two largest clusters showgain (n = 4,028) or
loss (n = 6,462) of H3K27ac during differentiation in all three
macrophage subtypes (Figure 1C and S1B). The closest genes
associatedwith differentiation gain or loss clusters are associated
with leukocyte differentiation, activation, metabolism, and phago-
cytosis (Table S2). Uponmonocyte exposure to LPS, H3K27ac in-
duction precedes a temporally delayed H3K4me1 (Figures 1C
and S1B). The closest genes associated with these enhancers
are involved in cytokine response and nuclear factor kB (NF-kB)
signaling, among other well-known LPS-response pathways (Ta-
ble S2). The ‘‘BG up/LPS down’’ enhancer cluster shows acceler-
ated H3K27ac deposition in BG-exposed monocytes and little to
no H3K27ac accumulation in LPS-exposedmonocytes relative to
naive-Mfs (Figure 1C). This cluster is composed of >3,200 en-
hancers and shows concordant increase in H3K4me1 to day 6
(Figure S1B). Chromatin segmentation analysis using EpicSeq
(Mammana and Chung, 2015) revealed that these regions gain
H3K4me1 at the expense of repressive H3K27me3 markings in
naive-Mfs and BG-Mfs (Figure S1D). Conversely, LPS-Mfs main-
tain a chromatin state more similar to monocytes, primarily low
H3K4me1 with the presence of H3K27me3 (Figure S1D). The
closest genes to these enhancers are involved in lipid biosyn-
thesis and lysosome and leukocyte differentiation (Table S2), indi-
cating that BG exposure leads to the accumulation of membrane
components necessary for phagocytosis and cytokine release,
whereas LPS exposure prevents their activation (Figure 1C).
Transcriptome Changes Modulated by LPS and
b-Glucan
RNA sequencing (RNA-seq) was performed on the same time
points as epigenetic marks (n = 2 donors; Figure 1A). General ki-
netics similar to those unveiled for epigenetic remodeling was
observable, with monocytes clustering after a short exposure
to BG and LPS (Figure 1D). Over the time course, the major
changes in gene expression patterns were associated with dif-
ferentiation (PC1, 55.8% of the variance) and LPS exposure
(PC2, 10.8% of the variance), which is most pronounced at
4 hr and day 1 (Figure 1D). Over 5,700 protein-coding genes
showed dynamic expression (fold change [FC] > 2, adjusted p
value [padj] < 0.05) in our model between either treatments or
time points (Table S3; Figures 1E and S2A). LPS-induced genes
(C) A total of 17,500 H3K27ac dynamic gene-distal regions were identified and can be clearly separated into four clusters: BG up/LPS down, LPS up, differ-
entiation gain, and differentiation loss. Solid lines aremedian log-FC relative to day 0, and shaded areas represent the 25th and 75th quartile. Naive cells are shown
as a green line, LPS as a red line, and BG as a purple line. H3K4me1 at these regions can be seen in Figure S1B; LPS induces early H3K27ac accumulation,
followed by long-term H3K4me1 marking, while BG induces concurrent accumulation of H3K27ac and H3K4me1.
(D) PCA plots showing the relationships among all samples based on dynamic gene expression. PC1 explains most of the variation and is associated with
differentiation. PC2 is LPS related, with LPS 4 hr and LPS day 1 samples separating from the corresponding naive and BG samples.
(E) Heatmap of differentiation associated genes, as well as those induced by LPS or BG exposure. The general trend in expression is that BG exposed cells start to
express differentiation associated genes faster (at day 1) than naive cells, while LPS exposed cells lag behind.
(F) Top pathways associated with differentiation and showing opposing directions in response to BG and LPS.
See also Figures S1, S2, and S3 and Tables S1, S2, S3, and S4.
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Figure 2. Motif Enrichment at Epigenetically Dynamic Promoters and Enhancers and Associated Transcription Factor Networks
Motif enrichment analysis was performed on ATAC-sequencing (nucleosome-free) peaks that overlap H3K27ac dynamic enhancers and H3K27ac promoters.
(A) Random forest (RF) and a partial least-squares (PLS) classifiers were trained using the TF motifs found by GIMME to determine features (TF motifs) based on
their ability to separate the 4 H3K27ac clusters shown in Figure 1C. Both classifiers produce a feature importance score (between 0 and 100), which is a measure
of how ‘‘characteristic’’ the presence or absence of the TF motif is for the considered cluster. Green dots represent positive features (motif over-represented in
cluster), and red dots represent negative features (motif under-represented in cluster). The EGR2motif was the strongest positive feature for the BG up/LPS down
(legend continued on next page)
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were involved in immune response, whereas LPS-delayed genes
were generally differentiation associated (Figure 1E; Table S4).
The major ontologies of BG-induced genes (662 genes at day
1) were lipid biosynthesis, metabolism, and the lysosome
pathway (Figure 1E; Table S4). Intersection between exposure-
dependent gene expression and promoter acetylation patterns
showed a strong overlap between H3K27ac and gene expres-
sion temporal profiles (Figures S2B and S2C).
LPS-Specific DNA (De)methylation Signatures
Recent studies have revealed extensive DNA methylation re-
modeling during B cell (Kulis et al., 2015) and osteoclast differen-
tiation (de la Rica et al., 2013; Nishikawa et al., 2015). Con-
sidering that our ex vivo differentiation model occurs in the
absence of cell division, we were interested to see the extent
to which (de)methylation plays a role during monocyte-to-
macrophage differentiation and innate immune memory. Unlike
the comprehensive histone modification remodeling, consistent
DNA methylation change (at least 30% change and four or
more significant differentially methylated CpGs per differentially
methylated region [DMR]) was limited to a few hundred genomic
regions (Figure S3). The vast majority of DMRs showed loss of
methylation during monocyte-to-macrophage differentiation
irrespective of MAMP exposure (Figure S3B), consistent with
recent findings in macrophages and dendritic cells (Vento-
Tormo et al., 2016). We did not observe a role for DNA methyl-
ation in ‘‘training’’ the macrophages for future transcriptional
response to infection. More than 90%of DMRs occurred at distal
elements marked by H3K4me1, and only 6% occurred at pro-
moters (Figure S3C). Cumulatively, our data indicate that LPS-
specific DNA methylation changes occur and, due to the more
stable nature of this mark, may represent a useful biomarker
for LPS-induced macrophage tolerance (Figures S3D and S3E).
LPS- and b-Glucan-Specific Transcriptional Networks
Motif analysis was used to gain insight into which pathways
and transcription factors (TFs) regulate the epigenetic changes
associated with differentiation and LPS or BG exposure. Four
clusters of enhancers and promoters were designated based
on H3K27ac dynamics over time: BG up/LPS down, ‘‘LPS up,’’
‘‘differentiation gain,’’ and ‘‘differentiation loss’’ (Figures 1C
and S1B). Two classifiers (random forest [RF] and a partial
least-squares [PLS]) were trained, using the TF motifs found by
GIMME (van Heeringen and Veenstra, 2011). Both score features
(TF motifs) were based on their ability to separate the clusters—
the so-called feature importance score (between 0 and 100)—
which is a measure of how characteristic the presence or
absence of the TF motif is for the considered cluster. Both
classifiers were trained with the caret R-package using 10-fold
cross-validation, repeated five times. We define positive (green
dots) and negative predictors (red dots) as TF motifs that are
more or less abundant of the considered cluster compared to
the other clusters, respectively.
Enhancers that show differentiation gain in H3K27ac were en-
riched for the SPI1 (PU.1) motif, while LPS-induced active en-
hancers were enriched for NF-kBmotif (Figures 2A and 2B).
The top positive predictor motif for the BG up/LPS down cluster
was EGR2, with a score of 100, followed by ARNT (Figure 2A).
EGR2 is downstream of dectin-1 (Goodridge et al., 2007) and
shows prominent, transient induction in BG-exposedmonocytes
(Figure S4A). Enhancers with EGR2motifs are mainly associated
with genes involved in lipid metabolism and biosynthesis and
lysosome function (Figures 1E and 1F). The early activation of
these pathways in BG may account for the higher expression
of LAMP1, the major component of the mature lysosome, in
BG-Mfs (Figure S4A).
Interestingly, LPS-exposed monocytes do not transiently acti-
vate EGR2 (Figure S4A). The discordant effect of BG and LPS on
EGR2 expression, the differential H3K27ac deposition at associ-
ated enhancers, and expression of downstream lipidmetabolism
genes suggests that this pathway plays a role in inducing trained
immunity as opposed to tolerance. In order to further confirm the
relationship between EGR2 and downstream lipid pathways, the
DNA-binding motif of EGR2 was scanned at the promoters of
known transcription factors, as well as lipid metabolism and
lysosome genes that are induced in BG-Mfs compared to mono-
cytes (Figure S4B). The EGR2motif was found at the promoter of
several highly expressed TFs, including MITF, which is a positive
identifier for the differentiation gain promoter cluster (Figure 2A),
and is also not activated in LPS-exposed monocytes (Fig-
ure S4A). Cumulatively, EGR2, MITF, and downstream TF motifs
were found at the promoters of 79% of induced lipid metabolism
and lysosome genes (Figure 2B). This analysis suggests that BG/
dectin-1-induced EGR2 activation leads to higher expression of
downstreamTFs (e.g., MITF) and the establishment of promoters
and enhancers that drive the expression of lysosomal and lipid
metabolism genes (Figure 2C). Given the importance of lipid
pathways in macrophage function, the opposing effect of LPS
and BG on these genes suggests that this pathway may play a
critical role in the low cytokine release in LPS-Mfs and elevated
release in BG-Mfs.
Transcriptional Response of Tolerized Macrophages to
LPS Re-exposure
Previous analysis in an ex vivomousemodel showed that tolerant
LPS-Mfs are impaired in their ability to produce pro-inflammatory
enhancer cluster, NF-kB for the LPS up cluster, SPI1 (PU.1) for the differentiation gain cluster, and JUNB for the differentiation loss cluster. At the promoter
regions NF-kB was a positive feature for LPS up cluster, MITF for the differentiation gain cluster, and CREB1 and JUNB for the differentiation loss cluster.
(B) Motif enrichment is plotted as absolute difference in abundance compared to background (yellow, higher abundance than background; blue, lower
abundance than background) for the top enriched motifs. Consistently identified transcription factor motifs include SPI1 at differentiation associated enhancers,
NF-kB at LPS enhancers, and EGR2 and MITF at BG enhancers. Abundance increase over background supports the level of importance score.
(C) A diagram of the transcription factor network based on EGR2 andMITFmotif occurrence at BG-induced lysosome and lipid metabolism genes. Purple arrows
indicate the direction of expression induced by BG exposure, and red arrows indicate the direction of expression induced by for LPS exposure. BG exposure
induces transient expression of the genes, while LPS exposure inhibits activation. The full network based on promoter abundance is shown in Figure S4B.
See also Figure S4.
1358 Cell 167, 1354–1368, November 17, 2016
cytokines, but maintain their ability to express other genes, such
as those required for tissue repair (Foster et al., 2007). Given the
wide-ranging epigenetic alterations in LPS-Mfs (Figure 1C; Table
S1), we sought to investigate the epigenetic basis for endotoxin
tolerance by exposing differentiated naive-Mfs, LPS-Mfs, and
BG-Mfs to LPS for 4 hr (LPS re-exposure) (Figure 3A). The overall
transcriptional and histonemodification changes induced inmac-
rophages by LPS re-exposure are shown in Figure 3B, and few
differences were observed between naive-Mfs and BG-Mfs.
LPS-Mfs show an avid response to LPS re-exposure both tran-
scriptionally andwithH3K27ac deposition at promoters and distal
enhancers (observable as large shift in PC2; Figure 3B). This indi-
cates that tolerized macrophages can and do respond to LPS at
the epigenetic and transcriptional level. However, from H3K27ac
and H3K4me1 principal-component analysis (PCA), it is clear that
the epigenetic profile of LPS-Mfs ismarkedly different from that of
naive-Mfs and BG-Mfs (observable as an LPS-Mfs lag on PC1;
Figure 3B).
Polytomous modeling was used to separate genes based on
their transcriptional response to LPS re-exposure (4 hr) in mac-
rophages at day 6. In total, 780 genes showed higher expression
(FC > 2, posterior probability > 0.3) in naive-Mfs following 4-hr
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Figure 3. Macrophage Endotoxin Tolerance Defined at the Transcriptional Level following LPS Re-exposure
(A) The innate immune memory model, including data collection at LPS re-exposure at day 6.
(B) PCA plots of dynamic RNA-seq, H3K27ac at promoters and enhancers, and H3K4me1 peaks, including LPS re-exposure samples. After re-exposure to LPS,
significant enhancer H3K27ac changes occur in LPS-Mfs, indicating that they are capable of activating their enhancers. However, the level of their response is
lower compared to monocytes, naive-Mfs, and BG-Mfs, which can be seen on the second principal component. Unlike RNA and H3K27ac, H3K4me1 does not
show significant changes following LPS re-exposure in any of the three macrophage subtypes.
(C) The total macrophage transcriptional response (750 genes) to LPS was separated into three groups based on the induction of genes in LPS-Mfs, relative to
naive-Mfs and BG-Mfs, revealing a gradient in LPS-Mf response to LPS re-exposure. The groups are (G1) tolerized genes, (G2) partially tolerized genes, and (G3)
responsive genes.
See also Figure S5.
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Figure 4. Histone Modification Dynamics and Open Chromatin Analysis at Tolerized Gene Promoters
(A) Heatmap showing average expression of 777 LPS-responsive genes in naive-Mfs. Genes are ranked based on their induction in LPS-Mfs, first by tolerance
group (G1, G2, and G3) and then by relative induction compared to naive-Mfs within each group. Response to LPS re-exposure is a gradient in LPS-Mfs, with the
most tolerized genes on the left and the most responsive genes on the right.
(B) Heatmap showing abundance of significant motifs in the promoter regions of the three macrophage LPS-responsive gene groups. The tolerized gene pro-
moters are enriched for several transcriptional repressors, such as EGR2 and TP53, while the partially tolerized gene promoters are enriched for IRF and STAT
motifs.
(C) Random forest (RF) and a partial least-squares (PLS) classifiers importance score (between 0 and 100) for each tolerized gene cluster (G1, tolerized; G2,
partially tolerized; and G3, responsive). Green dots represent over-represented motifs, and red dots under-represented motifs. The top features of G1 gene
(legend continued on next page)
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LPS exposure (Figure 3C; Table S5). Transcriptional responsive-
ness to LPS re-exposure in LPS-Mfs is a gradient, with genes
showing complete tolerance (unresponsiveness) (cluster G1), a
partial response (G2), or a full response comparable to naive-
Mfs (G3) (Figures 3C and S5A). Cytokine genes were the most
enriched group and were spread across the LPS re-exposure
response gradient, withCXCL9 (G1) and TNF (G2) showing com-
plete or partial tolerance and IL6 and IL8 showing comparable
responsiveness to naive-Mfs (G3) (Figures S5B and S5C). The
normal induction of interleukin 6 (IL-6) mRNA expression and
the absence of response in ELISA assays therefore suggests
that tolerance is a complex phenotype that involves both damp-
ened transcriptional responses to LPS re-exposure and an
inability to release some cytokines (Figure S5C). The top toler-
ance-specific biological process was ‘‘cytokine production,’’
while the top pathway was ‘‘RIG-I-like signaling’’ and ‘‘p53
signaling’’ (Figure S5D).
Epigenetic Profile of Tolerized Genes
To understand the molecular mechanisms involved in the altered
gene induction by LPS re-exposure in LPS-Mfs, we investigated
promoter motif enrichment at overlapping assay for transposase
accessible chromatin (ATAC) peaks. Because transcriptional
responsiveness to LPS re-exposure in tolerized macrophages
occurs on a gradient (Figure 4A), motif enrichment at promoters
was scanned in a sliding window of 100 promoters throughout
the response gradient from most tolerized (G1) to responsive
(G3) genes (Figure 4B). This analysis identified discrete motif sig-
natures in theG1andG2 tolerizedgroups. TheG1genepromoters
were enriched for several TF motifs, including EGR2, HIF1A, and
p53. The latter TF was also identified as a top tolerized pathway
(Figure S5D). The partially tolerized genes are enriched for IRF
and STAT motifs (Figure 4B). Random Forest analysis also indi-
cated that EGR2 was the top identifier for the G1 group, while
IRF and STATmotifs are top identifiers for the G2 group. Interest-
ingly, theG3groupdoesnotcontainpositive identifiers (Figure4C).
IRF and STAT genes show a tolerized pattern (Figure S6A), indi-
cating that their unresponsiveness to LPS effects downstream
partially tolerized genes. On the other hand, NFKB1 and RELA
showed normal induction in LPS-Mfs (Figure S6B).
Dynamic H3K27ac change during differentiation and LPS or
BG exposure was plotted over the promoter regions of G1, G2,
and G3 genes (Figure 4D). Dynamic promoter H3K27ac was
observed for roughly half of all genes, with the rest showing
consistent high acetylation during all time-points, including
LPS re-exposure (not shown). Tolerized genes (G1) and partially
tolerized genes (G2) showed no or impaired accumulation of
H3K27ac, respectively, after LPS re-exposure in LPS-Mfs
compared to naive-Mfs and BG-Mfs (Figure 4D), while respon-
sive genes (G3) were equally acetylated after LPS re-exposure
in all subtypes (Figure 4D). H3K4me3 patterns at these pro-
moters closely matched those of H3K27ac (Figure S5B). This
finding suggests that LPS-Mfs fail to accumulate H3K27ac at to-
lerized genes either through absence of pro-inflammatory acti-
vators, such as IRF and STATs in the case of G2 genes, or
through presence of tolerance inducing TFs, such as HIF1A in
the case of G1 genes.
b-Glucan Exposure Can Reverse Tolerance in Both
In Vitro and In Vivo LPS-Exposed Monocytes
As indicated before, BG and LPS have an opposing effect on
EGR2 and MITF expression (Figure S4A), accumulation of
H3K27ac at target enhancers and promoters (Figure 1C), and
expression of genes involved in macrophage function, such as
lipid metabolism and lysosome and cytokine production (Fig-
ure 1E). These findings point to a potential for reversal of LPS-
induced tolerance by using BG to stimulate the dectin-1
pathway. To test this hypothesis, monocytes were exposed to
LPS for 24 hr and then to BG for 24 hr, followed by a rest period
before LPS re-exposure (Figure 5A). We refer to these macro-
phages as ‘‘rescue-Mfs’’. Additionally, we used the clinically
relevant small molecular histone mimic bromodomain and extra-
terminal domain family (BET) inhibitor (IBET)151 in a co-treat-
ment with LPS (‘‘preventative’’) or following LPS exposure
(‘‘reversal’’) setting (Figure 5A). ELISAs showed that BG expo-
sure was able to reverse LPS-induced tolerance and reinstate
normal levels of cytokine release in rescue-Mfs (Figure 5B). On
the other hand, IBET151 was only effective in preventing toler-
ance when used to block the LPS-induced response, but it did
not reverse tolerance when administered after LPS (Figure 5C).
This is in line with the finding that IBET151 is effective in blocking
inflammation-associated death in mice (Nicodeme et al., 2010)
but suggests that IBET151 is not an effective treatment in
monocytes that have already experienced an inflammatory
response. Therefore, BG represents a possible treatment option
for restoring proper macrophage cytokine release during the
post-inflammation tolerance phase.
The suitability of the in vitro tolerance model to mimic the
in vivo situation is a major question. Chiefly, does LPS exposure
in vivo induce the same transcriptional responses in monocytes,
and can in vivo LPS-induced tolerance be reversed by BG? To
answer these questions, we used an in vivo experimental human
endotoxemia model (Draisma et al., 2009) (Figure 5D). In this
model, healthy volunteers are injected with 2 ng/kg US Standard
Reference Endotoxin Escherichia coli O:113 LPS (Pharmaceu-
tical Development Section of the National Institute of Health, Be-
thesda, MD, USA), which leads to a sepsis-like state (reviewed in
Bahador and Cross, 2007). Study protocols were approved by
the local ethics committee of the Radboud University Nijmegen
Medical Centre. The volunteers experience transient fever and
cold chills as well as pro- and anti-inflammatory cytokine signa-
tures. The in vivo LPS-exposed monocytes show elevated
promoters are E2F3, EGR2, and ZBTB7B motifs. The top features for G2 gene promoters are IRF and STAT, while G3 promoters do not have over-represented
features but are depleted of EGR2, E2F3, and ZNF350.
(D) Median H3K27ac at dynamic promoters of G1, G2, and G3 group genes, shaded areas represent the 25th and 75th quartile. This shows that LPS-Mfs do not
accumulate H3K27ac at tolerized genes but do so at the promoters of responsive genes. See also Figure S6 for H3K4me3.
See also Figure S6.
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mRNA expression of key cytokines at 4 hr (not shown) and fail to
release cytokines in response to a second ex vivo LPS exposure.
In this regard, they behave much like in vitro LPS-tolerized
monocytes. Monocytes were isolated from peripheral blood
taken before and after LPS administration, and then exposed
ex vivo to either culture medium alone, or with BG. Cytokine
release wasmeasured following LPS re-exposure in culture (Fig-
ure 5D). Ex vivo BG exposure increased the release of tumor ne-
crosis factor (TNF) and IL-6 in tolerized monocytes at LPS re-
exposure (Figures 5B and 5C). This finding indicates that BG
can restore cytokine production of in-vivo-tolerized monocytes.
Cumulatively, this confirms that the mechanisms involved in the
establishment of tolerance by LPS in vivo and in vitro are similar,
validating the use of the in vitro model to study reversal of toler-
ance by BG. More importantly, it suggests that the BG effect on
monocyte tolerance may be transferred to the clinic in the future.
b-Glucan Recovers the Transcriptional Response to LPS
at Tolerized Genes
Next, we assessed whether BG reverses tolerance at the tran-
scriptional level. In this experimental setup, monocytes were
exposed to LPS followed by BG and then left to rest 24 hr or
4 days before LPS re-exposure for 4 hr (Figure 6A). Additionally,
monocytes were treated with a combination of LPS and IBET151
(preventative) and LPS followed by IBET151 (reversal). BG was
able to recover the induction of 60% of tolerized genes at day
6 (Figure 6A), including several pro-inflammatory TFs (Figure 6B).
Similar effects were observed when IBET151 was used in a pre-
ventative model, indicating that BG reversal of LPS-induced
tolerance leads to an outcome similar to that produced by block-
ing LPS-induced tolerance altogether. Overall BG reversal led to
a higher median expression of tolerized genes compared to both
preventative and reversal use of IBET151 (Figure 6A).
Epigenomic Analysis of b-Glucan Recovery of Tolerized
Macrophages
BG exposure following LPS exposure recovers the expression of
genes involved in lipid biosynthesis, phagocytosis, and cytokine
transport (Figures S7A and S7B). Recovery of expression was
observedasearly asday3 andmaintainedat ahigher level inmac-
rophages at day 6 (Figure S7B). Interestingly, addition of BG to
naive and tolerized monocytes at day 1, elicited the expression
of EGR2 and MITF within 4 hr, with a lower induction in tolerized
monocytes (Figure S7C). These findings indicate that BG-induced
receptorpathways remain at least partially inducible after theLPS-
induced cytokine response and that these pathways can partially
recover the naivemacrophage epigenetic and transcriptional pro-
grams. Analysis of dynamic H3K27ac promoters and enhancers
in naive-Mfs, LPS-Mfs, rescue-Mfs, and LPS-co-IBET151-Mfs
revealed that BG exposure restores H3K27ac deposition at re-
gions where H3K27ac increase was not obtained following LPS
exposure (Figure 7). Interestingly, while IBET151 blocks 75%
of the transcriptional response to LPS in monocytes at 4 hr (data
not shown), LPS-co-IBET151-Mfs look more like LPS-Mfs at day
6, indicating noeffect of IBET151on the overall epigenomic profile
of LPS-Mfs (Figure 7A, blue square). The effect of BGexposure on
H3K27ac deposition in LPS-Mfs was observable at both pro-
moters and distal enhancers of genes involved in metabolism
and lipid biosynthesis (Figures 7C and 7D).
DISCUSSION
Perturbation of normal monocyte-to-macrophage differentiation
by exogenous signals, such as high bacterial burden in sepsis,
can lead to a changed chromatin state and an associated devi-
ation from steady-state function (Amit et al., 2016). This phenom-
enon is known as innate immune memory, with the best-charac-
terized outcomes being endotoxin tolerance or trained innate
immunity (Netea et al., 2016). Trained immunity can have bene-
ficial effects through priming of macrophages for stronger re-
sponses to subsequent infection and can be induced by a variety
of MAMPs, such as C. albicans (Quintin et al., 2012), Bacille
Calmette-Gue´rin (BCG) vaccine (Kleinnijenhuis et al., 2012),
and BG (Saeed et al., 2014). Conversely, exposure to high levels
of LPS can induce a tolerizedmacrophage phenotype, which is a
major cause of sepsis-associated mortality (SepsisReport,
2012). Previously, we showed that tolerized macrophages
(LPS-Mfs) and trained macrophages (BG-Mfs) have distinct
epigenetic (Saeed et al., 2014), and metabolic states (Cheng
et al., 2014). Mouse studies have shown that such distal element
markings are important for appropriate responses to infection
(Ghisletti et al., 2010; Ostuni et al., 2013) and identity of tissue-
resident macrophages (Amit et al., 2016; Lavin et al., 2014).
Nevertheless, until now, the epigenetic basis for endotoxin toler-
ance in humans has not been explored.
In the current study, our aim was to unveil the early epigenetic
and transcriptional events following monocyte exposure to LPS
or BG and how the resulting epigenetic landscapes determine
the function of tolerized and trained macrophages. LPS- and
BG-induced active histone dynamics were observed as early
as 1 hr and 4 hr after exposure, respectively (Figures 1B and
1C). Generally, H3K27ac accumulation was accompanied by
H3K4me1 accumulation, most obviously at BG-induced en-
hancers (Figure S1B). Contrary to this general pattern, LPS-
induced active enhancers, associated with an inflammation
response, showed discordance in time with accumulation of
H3K4me1 (Figure S1B), which remained at higher levels in
LPS-Mfs compared to naive-Mfs and BG-Mfs. This persistence
of H3K4me1 in LPS-Mfs contributes to the overall epigenetic
signature of this macrophage subtype and may account for
some of the tolerized phenotype (Figure 1B). More pointedly,
we discovered a set of more than 3,000 de novo macrophage
(C) Preventative use of IBET blocks the first LPS response in monocytes, resulting in differentiation of macrophages that can release cytokines at the second LPS
exposure. Therapeutic use of IBET does not re-instate cytokine release in macrophages.
(D) Experimental human endotoxemia model, with ex vivo BG administration. Monocytes were isolated from 12 healthy volunteers before (naive) and 4 hr after
LPS injection (tolerized). Naive or tolerized monocytes were exposed to BG for 24 hr, followed by culture media, or culture media alone. After 3 days ex vivo,
monocytes were re-exposed to LPS, and cytokines were measured 24 hr later.
(E and F) BG recovered IL-6 release in 9 out of 12 tolerized monocytes (E) and TNF release in 8 out of 12 monocytes (F). Data are presented as mean ± SD.
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established distal enhancers that were modulated in the oppo-
site direction by BG or LPS exposure (Figure 1D). Deposition of
H3K27ac and H3K4me1 at these regions was accelerated by
BG exposure and delayed or completely blocked by LPS expo-
sure. Accordingly, expression of genes near these elements was
induced by BG, peaking at 24 hr post-exposure, while they re-
mained lowly expressed in LPS-exposedmonocytes (Figure 1F).
These genes were involved in lipid metabolism and biosynthesis,
phagocytosis, and lysosomematuration (Figures 1G and S2) and
have clear TF motif signatures for EGR2, MITF, and ARNT (Fig-
ure 2A). Interestingly, EGR2, a TF downstream of the BG recep-
tor dectin-1, showed clear transient upregulation by BG but re-
mained inactive in LPS-exposed monocytes, suggesting a
possible role in modulating these pathways (Figure S4). TFs
and pathways linking lipid biosynthesis and inflammation have
been described (Spann et al., 2012). Further, macrophage
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Figure 6. Reversal of Tolerance by BG at the Transcriptional Level
(A) Heatmap of the transcriptional response of naive-Mfs, LPS-Mfs, and rescue-Mfs (BG reversed LPS-Mfs) to LPS re-exposure at day 6. The scale represents
relative expression between LPS exposed naive-Mfs (1) and LPS-Mfs (0). Rescue-Mfs exposed to LPS show the most similar profile to naive-Mfs. On the top of
the heatmap is median expression (log2 RPKM) of tolerized genes at day 6 and LPS re-exposure in naive-Mfs (black), LPS-Mfs (red), LPS-co-IBET-Mfs (blue),
LPS + IBET-Mfs (light blue), and rescue-Mfs (purple).
(B) BG reverses the tolerization of key LPS-induced transcription factors, such as STAT2, STAT5A, IRF1, and IRF8. Log2 fold change increase in mRNA
expression is shown.
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response to infection requires a substantial amount of energy,
and shifts in metabolism and energy production are a whole
mark of macrophage polarization to M1 or M2 subtypes (Ghes-
quie`re et al., 2014), as well as for establishment of trained immu-
nity (Cheng et al., 2014).
Reversal of tolerance after the initial inflammation phase has
garnered interest because of the limited success of inflamma-
tion-blocking treatments to reduce overall sepsis mortality
(Angus and van der Poll, 2013) and because the majority of
sepsis deaths occur due to secondary hospital infection during
the tolerized phase (Gilroy and Yona, 2015). Our hypothesis
was that BG can reverse LPS-induced tolerance because it
discordantly regulated pathways that LPS also affected. Specif-
ically, LPS fails to activate key regulators of lipid, lysosome, and
metabolism genes, EGR2 and MITF, while BG induces their
expression (Figures 1 and 2). Recently, IFNG was shown to
partially recover metabolic function in tolerized monocytes
from sepsis patients, indicating that reversal of tolerance using
innate immune ‘‘trainers’’ is a viable therapeutic strategy (Cheng
et al., 2016). We show that BG exposure can indeed reverse the
tolerance in macrophages induced by LPS exposure, with
rescue-Mfs showing higher release of cytokines in response to
a second LPS stimulus (Figures 5A–5C). This was in contrast to
the inflammation blocker IBET151, which only prevented toler-
ance when used to block the initial LPS response but could not
reverse it when given to cells after LPS-induced inflammation
(Figure 5). In order to further relate our findings to the in vivo sit-
uation, we used an experimental human endotoxemia model to
induce tolerance in vivo (Draisma et al., 2009; Kox et al., 2014).
In terms of cytokine production, in-vivo-tolerized monocytes
behave similarly to their in-vitro-tolerized counterparts. The to-
lerized state of in vivo LPS-exposed monocytes is similar to
that of ex-vivo-exposed monocytes and, most importantly, can
also be rescued by ex vivo BG exposure (Figures 5D–5F),
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See also Figure S7.
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indicating that the mechanisms controlling monocyte tolerance
in vivo can also be reverted to a more responsive phenotype.
In order to determine the ability of BG to reverse tolerance at
the molecular level, we first characterized the transcriptional
and epigenetic response to a second LPS exposure in tolerized
macrophages (Figures 3 and 4). Studies in mouse sepsis models
and human sepsis patients have shown that rather than being
inert in response to a second LPS exposure, tolerized macro-
phages show a shift in the specific pathways that they activate
(Foster et al., 2007; Shalova et al., 2015). In line with these
studies, we show that LPS-Mfs remodel both H3K27ac and
gene expression in response to LPS (Figure 3B). However, the
starting point of LPS-Mfs is significantly different from that of
naive and BG-Mfs, most clearly for H3K4me1 marked en-
hancers, suggesting that while activation is occurring, the avail-
able enhancer repertoire of these cells is limited or not suited.
Our analysis identified a gradient in the LPS-Mf response to
LPS, with some genes showing a tolerized pattern (no induction)
and others showing a responsive pattern (Figure 3C). The most
tolerized gene promoters were enriched for EGR2, HIF1A, and
p53 motifs, among many others. A potential role for HIF1A is in
agreement with a recent transcriptional analysis in monocytes
from sepsis patients (Shalova et al., 2015), while the p53
pathway was a top-ranked tolerized identified by Gene Ontology
(GO) analysis (Figure S5D). The strongest enrichment at partially
tolerized genes was for the IRF and STAT TF motifs that show
strong tolerized expression patterns themselves, ie, IRF1,
IRF8, STAT2, and STAT5A (Figure S6A). IRF8 and its down-
stream target, KLF4, both of which are important regulators of
monocyte differentiation (Kurotaki et al., 2013), show a tolerized
profile and enrichment at tolerized gene promoters (Figure 4B).
Other, non-TF regulators of tolerance, such as IRAK3, HIF1A,
SOCS3, and IDO1, are all more highly expressed in LPS-Mfs
compared to naive-Mfs and BG-Mfs and have previously been
associated with endotoxin-induced tolerance (Bessede et al.,
2014; Saeed et al., 2014; Shalova et al., 2015).
Rescue macrophages (BG exposed following LPS exposure)
were able to induce60%of tolerized genes at LPS re-exposure
(Figure 6). This indicates that BG reversal of tolerance at the tran-
scriptional level is not complete (Figure 6A). Fascinatingly, BG
recovered the expression of tolerized genes to a level greater
than that observed in macrophages treated with IBET and LPS
together (Figure 6A). This indicates that BG can reinstate a
responsive state at a higher level than that obtained by actually
blocking the initial LPS transcriptional response. This important
observation suggests that BG-associated pathways remain
intact even after large-scale epigenetic and transcriptional pro-
grams are induced by LPS. At the level of histone modifications,
BG recovers H3K27ac at regions that are silent in LPS-Mfs,
further supporting the notion that the molecular mechanisms
required for BG-induced chromatin remodeling remain after
the initial LPS response (Figures 7 and S7).
In conclusion, the hypothesis-free epigenomic and transcrip-
tomic analysis of monocyte-to-macrophage differentiation and
innate immune memory generated a number of testable hypoth-
eses. Our findings show that the innate immune ‘‘training stim-
ulus’’ b-glucan can reverse macrophage tolerance ex vivo. This
is an important step toward understanding how the tolerized
phenotype can be reversed in sepsis patients and ultimately pro-
vides the framework for future therapeutic developments in
innate immune diseases.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit polyclonal anti-H3K27ac Diagenode pAb-196-050
Rabbit polyclonal anti-H3K4me1 Diagenode pAb-037-050
Rabbit polyclonal anti-H3K4me3 Diagenode pAb-003-050
Rabbit polyclonal anti-H3K27me3 Diagenode pAb-195-050
Rabbit polyclonal anti-H3K9me3 Diagenode pAb-193-050
Chemicals, Peptides, and Recombinant Proteins
IBET-151 GSK Epinova and Cellzome GSK1210151A
Human Serum Sigma-Aldrich H4522-100ML
RPMI 1640 Medium, GlutaMAX Thermo Fisher Scientific 61870036
Gentamycin Thermo Fisher Scientific 15750060
L-glutamine Thermo Fisher Scientific 25030081
Sodium Pyruvate Thermo Fisher Scientific 11360070
Percoll Sigma-Aldrich P1644-1L
Ficoll Paque Plus Sigma-Aldrich GE17-1440-03
Lipopolysaccharides from Escherichia coli
055:B5
Sigma-Aldrich L2880-10MG
b1,3(D)glucan (b-glucan) (Saeed et al., 2014) N/A
2-Mercaptoethanol Thermo Fisher Scientific 21985023
Actinomycin D Thermo Fisher Scientific 11805017
IGEPAL CA-630 Sigma-Aldrich I8896-50ML
Critical Commercial Assays
KAPA library preparation kit Kapa Biosystems KK8400
riboZero gold rRNA removal kit Illumina MRZG12324
Nextera DNA Library Prep Kit Illumina FC-121-1031
TruSeq SBS KIT v3 - HS (50 cycles) Illumina FC-401-3002
NextSeq 500/550 High Output v2 kit (75 cycles) Illumina FC-404-2005
NEBNext High-Fidelity 2 3 PCR Master Mix New England Biolabs M0541
iQ SYBR Green Supermix Bio-Rad 1708880
100 3 SYBR Green I Nucleic Acid Gel Stain Thermo Fisher Scientific S7563
Human IL-6 elisa Sanquin M9316
Human TNFa elisa R&D DY210
SPRIselect reagent kit Beckman Coulter B23218
E-Gel SizeSelect Agarose Gels, 2% Thermo Fisher Scientific G661002
CD3 MicroBeads, human Miltenyi Biotec 130-050-101
CD19 MicroBeads, human Miltenyi Biotec 130-050-301
CD56 MicroBeads, human Miltenyi Biotec 130-050-401
dNTP set 100 mM Life Technologies 10297-018
dUTP 100 mM Promega U119A
Glycogen (20 mg/ml) Life Technologies 10814-010
Random Hexamer primers Sigma-Aldrich 11034731001
Second Strand Buffer Life Technologies 10812-014
Superscript III Reverse Transcriptase Life Technologies 18080-044
DNA polymerase I, E. coli New England Biolabs M0209S
USER enzyme New England Biolabs M5505L
(Continued on next page)
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CONTACT FOR REAGENTS AND RESOURCE SHARING
Further information and requests for reagents may be directed to, and will be fulfilled by the corresponding author Hendrik G. Stun-
nenberg (h.stunnenberg@ncmls.ru.nl).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Monocytes from Healthy Donors
All primary cells were isolated from healthy volunteers who gave written informed consent (Sanquin Blood bank, Nijmegen, the
Netherlands). Volunteers are of Northern European descent. Peripheral blood mononuclear cells were isolated by centrifugation in
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
E.Coli Ligase New England Biolabs M0205L
Rnasin Plus Rnase Inhibitor Promega N2615
Ribonuclease H Life Technologies AM2293
T4 DNA polymerase New England Biolabs M0203L
Sodium Acetate (3M) Life Technologies AM9740
DNase I QIAGEN 79254
Qubit RNA HS assay kit Life Technologies Q32852
Ribozero Gold Kit Illumina MRZG12324
Rneasy Mini Kit QIAGEN 74106
Deposited Data
Raw data files for RNA sequencing This paper GEO: GSE85243
Raw data files for ChIP sequencing This paper GEO: GSE85245
Raw data files for ATAC sequencing This paper GEO: GSE87218
Raw data files for WGBS sequencing This paper EGA: EGAD00001002693
Experimental Models: Organisms/Strains
Human: primary monocytes from healthy
volunteers
Sanquin Blood Bank N/A
Sequence-Based Reagents
NEXTflex DNA Barcodes - 48 Bioo Scientific 514104
Primer EGR2: F 50 TTGACCAGATGAACGGAGTG
30R 50 GTTGAAGCTGGGGAAGTGAC 30
This paper N/A
Primer MITF: F 50 AACTCATGCGTGAGCAGATG
30R 50 TACTTGGTGGGGTTTTCGAG 30
This paper N/A
Primer CSF1: F 50 CAGATGGAGACCTCGTGCC
30R 50 GCATTGGGGGTGTTATCTCTG 30
This paper N/A
Primer LAMP1: F 50 TGAACAAGACAGGCCT
TCCC 30R 50 TGTGCAGCTCCAGAGTCACC 30
This paper N/A
Software and Algorithms
Bedtools (Quinlan and Hall, 2010) http://bedtools.readthedocs.io/en/latest/
Bamtools (Barnett et al., 2011) https://github.com/pezmaster31/bamtools
Samtools (Li and Durbin, 2009) http://samtools.sourceforge.net/
GSNAP (Wu and Nacu, 2010) http://research-pub.gene.com/gmap/
GimmeMotifs (van Heeringen and Veenstra, 2011) https://github.com/simonvh/gimmemotifs
Caret (Kuhn, 2008) http://cran.r-project.org/web/packages/caret/
index.html
HOMER (Heinz et al., 2010) http://homer.salk.edu/homer/motif/
DAVID (Huang da et al., 2009) https://david.ncifcrf.gov/
bwa (Li and Durbin, 2009) http://bio-bwa.sourceforge.net/
bowtie (Langmead et al., 2009) http://bowtie-bio.sourceforge.net/index.shtml
MACS2 (Zhang et al., 2008) https://github.com/taoliu/MACS
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Ficoll-Paque (GE Healthcare), followed by removal of T cells using an additional Percoll gradient. Monocytes were purified from
PBMCs using negative selection in an LD column magnet separator, with beads for CD3+ (T cells), CD19+ (B cells) and CD56+
(NK cells) positive cells (Miltenyi Biotech), yielding > 95% pure monocytes. Successful isolation of monocytes was confirmed with
FACS, as previously described (Saeed et al., 2014).
In Vitro Monocyte-to-Macrophage Differentiation and Induction of Innate Immune Memory
Monocytes were differentiated into resting macrophages by ex vivo culture in RPMI 1640 medium (Sigma Aldrich) with 10% Human
Serum. Media was supplemented with 10 mg/mL gentamycin, 10 mM L-glutamine and 10 mM pyruvate (Life Technologies). Toleriza-
tion was induced by treatment of monocytes with 10-100ng/mL LPS for 24 hr, followed by washout and five days culture in RPMI +
10% human serum, while trained innate immunity was induced by treatment with 5 mg/mL BG for 24 hr, followed by washout and
5 days in culture. Establishment of tolerance or training in the resultingmacrophages at day 6 was determined by TNF and IL6 release
at 24 hr following LPS stimulation using ELISA. For ChIP-seq, 10x106 monocytes were seeded in 10cm dishes, for RNaseq and
ATAC-seq 1.5 3 106 monocytes were seeded in 6 well plates. IBET151 (GSK) was diluted to 50 mM stock using DMSO. Following
dosage titration 5 mM was determined as the appropriate final concentrations to prevent tolerization, without causing cell death.
IBET-151 was added to monocytes at the same time as LPS for 24 hr, followed by washout and five days culture in RPMI + 10%
human serum to macrophage differentiation.
Experimental Human Endotoxemia Model
In vivo endotoxin tolerance was examined in 12 healthy nonsmoking volunteers who participated in an experimental human endo-
toxemia study. The study is registered at Clinicaltrials.gov (NCT02602977) and study protocols were approved by the local ethics
committee of the Radboud University Nijmegen Medical Centre (NL53584.091.15/CMO 2015-1796). Written informed consent
was obtained from all study participants. Subjects were screened before the start of the experiment and had a normal physical ex-
amination, electrocardiography, and routine laboratory values. Throughout the study period, subjects were not allowed to take any
drugs, including acetaminophen, and were asked to refrain from alcohol and caffeine 24 hr and from food 12 hr before the start of the
endotoxemia experiment. All study procedures were conducted in accordance with the declaration of Helsinki including current re-
visions and Good Clinical Practice guidelines. Experimental human endotoxemia was conducted as described previously (Kox et al.,
2014). Briefly, all subjects received an intravenous bolus injection of LPS (lipopolysaccharide derived from Escherichia coli O:113,
Clinical Center Reference Endotoxin, National Institutes of Health (NIH), Bethesda, MD) at a dose of 2 ng/kg. Blood was obtained
before LPS administration and 4 hr afterward, and monocytes were isolated. Monocytes were exposed to culture or BG ex vivo,
and cytokine production in the supernatants was measured following ex vivo LPS (10ng/ml) exposure. Cytokine production was
determined by ELISA following the protocol of the manufactures (IL-6, sanquin and TNFa, R&D systems).
METHOD DETAILS
Cytokine Assays
TNFa and IL-6 were measured using ELISA according to the manufacturer protocol (IL6: Sanquin; and TNFa: R&D). For cytokines
production assays the differences between groups were analyzed using the Wilcoxon signed-rank test. The level of significance
was defined as a p value < 0.05.
RNA Extraction and cDNA Synthesis
Total RNA was extracted from cells using the QIAGEN RNeasy RNA extraction kit (QIAGEN, Netherlands), using on-column DNaseI
treatment. Ribosomal RNA was removed using the riboZero rRNA removal kit (Illumina). RNA was then fragmented into 200bp frag-
ments by incubation for 7.5 min at 95C in fragmentation buffer (200 mM Tris-acetate, 500 mM Potassium Acetate, 150 mM Mag-
nesium Acetate [pH 8.2]). First strand cDNA synthesis was performed using SuperScript III (Life Technologies), followed by synthesis
of the second cDNA strand. Library preparation was performed using the KAPA hyperprep kit (KAPA Biosystems). Quality of cDNA
and the efficiency of ribosomal RNA removal was confirmed using quantitative RT-PCR using the IQ Sybr Supermix, with primers for
GAPDH, 18S and 28S rRNA.
Chromatin Immunoprecipitation
Purified cells were fixed with 1% formaldehyde (Sigma) at a concentration of approximately 10 million cells/ml. Fixed cell prepara-
tions were sonicated using a Diagenode Bioruptor UCD-300 for 3x 10 min (30 s on; 30 s off). 67 ml of chromatin (1 million cells) was
incubated with 229 ml dilution buffer, 3 ml protease inhibitor cocktail and 0.5-1mg of H3K27ac, H3K4me3, H3K4me1, H3K27me3,
H3K9me3 or H3K36me3 antibodies (Diagenode) and incubated overnight at 4C with rotation. Protein A/G magnetic beads were
washed in dilution buffer with 0.15% SDS and 0.1%BSA, added to the chromatin/antibody mix and rotated for 60 min at 4C. Beads
werewashedwith 400ml buffer for 5min at 4Cwith five rounds of washes. After washing chromatin was eluted using elution buffer for
20 min. Supernatant was collected, 8 ml 5M NaCl, 3ml proteinase K were added and samples were incubated for 4 hr at 65C.Finally
samples were purified using QIAGEN; Qiaquick MinElute PCR purification Kit and eluted in 20 ml EB. Detailed protocols can be found
on the Blueprint website (http://www.blueprint-epigenome.eu/UserFiles/file/Protocols/Histone_ChIP_May2013.pdf).
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Library Preparation for Sequencing
Illumina library preparationwas done using the KapaHyper Prep Kit. For end repair and A-tailing double stranded DNAwas incubated
with end repair and A-tailing buffer and enzyme and incubated first for 30 min at 20C and then for 30 min at 65C.Subsequently
adapters were ligated by adding 30ml ligation buffer, 10 Kapa l DNA ligase, 5 ml diluted adaptor in a total volume of 110ml and incu-
bated for 15min at 15C. Post-ligation cleanupwas performed using Agencourt AMPure XP reagent and products were eluted in 20 ml
elution buffer. Libraries were amplified by adding 25 ml 2x KAPA HiFi Hotstart ReadyMix and 5ml 10x Library Amplification Primer Mix
and PCR, 10 cycles. Samples were purified using the QIAquick MinElute PCR purification kit and 300bp fragments selected using
E-gel. Correct size selection was confirmed by BioAnalyzer analysis. Sequencing was performed using Illumina HiSeq 2000
machines and generated 43bp single end reads. Samples for RNA-seqwere treated to the above protocol exactly, except for a single
additional step: After post-ligation cleanup, and before library amplification, samples were incubated with 3 uL USER enzyme for
15 min at 37C to digest the 2nd cDNA strand.
Assay for Transposase Accessible Chromatin
Monocytes or macrophages (100,000 cells) were scrapped in a well of a 6-well plate with cold PBS and then spun down at 8003 g for
5 min at 4C. Cells were washed with 50 ml of cold 1x PBS buffer, incubated in 50 ml of cold lysis buffer (10 mM Tris-HCL (pH 7.4),
10 mMNaCl, 3 mMMgCl2 0, 1% IGEPAL) and spun down at 8003 g for 10 min at 4C. The nuclei were immediately resuspended in
the transposition reaction mix (22.5 ml TD buffer, 2.5 ml Tn5 Transposase, 25 ml NF H2O) and incubated for 30 min at 37C. Following
transposition, 100 ml AMPure beads were added to the reaction (sample-to-bead ratio of 1:2), mixed thoroughly by pipetting, and
incubated for 15 min at RT. Samples and beads were washed on the magnetic rack with 80% ethanol, dried for 5 min, and resus-
pended in 15 ml EB buffer. DNA was amplified with 10 - 15 PCR cycles using the mix (15 ml transposed DNA, 0.3 ml 100x SYBR Green
I, 25 ml NEBNext High-Fidelity master mix, 2.5 ml Nextera Primer index N7.. (25 mM), 2.5 ml Nextera Primer index S5.. (25 mM), 4.7 ml NF
H2O). In order to reduce GC and size bias in PCR, the PCR reaction is monitored using qPCR to stop amplification prior to saturation.
Following amplification, samples were incubated purified twice using SPRI beads, first using negative selection with a sample-to-
bead ratio of 1-0.65 and then positive selection with a sample-to-bead ratio of 1-1.8. After 80% Ethanol wash and drying, the sample
was eluted in 20 ml EB buffer, and quality checked before sequencing. Detailed protocol can be found on the Blueprint website (http://
www.blueprint-epigenome.eu/UserFiles/file/Protocols/ATAC_Seq_Protocol.pdf).
Whole Genome Bisulfite Sequencing
Genomic DNA (1-2 mg) was spikedwith unmethylated lDNA (5ng of lDNAper mg of genomic DNA) (Promega). The DNAwas sheared
by sonication to 50-500bp using a Covaris E220 and fragments of size 150-300 bpwere selected using AMPure XP beads (Agencourt
Bioscience). Genomic DNA libraries were constructed using the Illumina TruSeq Sample Preparation kit (Illumina) following the
lllumina standard protocol: end repair was performed on the DNA fragments, an adenine was added to the 30 extremities of the frag-
ments and Illumina TruSeq adapters were ligated at each extremity. Adter adaptor ligation, the DNAwas treated with sodium bisulfite
using the EpiTexy Bisulfite kit (QIAGEN) following the manufacturer’s instructions for formalin-fixed and paraffin-embedded (FFPE)
tissue samples. Two rounds of bisulfite conversion were performed to assure a high conversion rate. An enrichment for adaptor-
ligated DNA was carried out through 7 PCR cycles using the PfuTurboCx Hotstart DNA polymerase (Stratagene). Library quality
was monitored using the Agilent 2100 BioAnalyzer (Agilent), and the concentration of viable sequencing fragments (molecules car-
rying adaptors at both extremities) estimated using quantitative PCR with the library quantification kit from KAPA Biosystem. Paired-
endDNA sequencing (2x100 nucleotides) was then performed using the Illumina Hi-Seq 2000.WGBSdata are available upon request
from the BLUEPRINT consortium.
RNA-Seq Data Analysis
For quality control and visualization, RNA-seq reads were aligned to the hg19 reference genome using GSNAP (Wu and Nacu, 2010)
with non-default parameters -m 1 -N 1 -n 1 -Q -s Ensembl_splice_68. Each RNA-seq sample was subjected to a quality control step,
where, based on read distribution over the annotated genome, libraries that are outlierswere identified and discarded from further anal-
ysis. To infer gene expression levels, RNA-seq reads were aligned to the Ensembl v68 human transcriptome using Bowtie. Quantifica-
tion of gene expression was performed using MMSEQ. Differential expression was determined using MMDIFF. A two model compar-
ison was used to identify differentially expressed genes that confer cellular identity Mo/Mf. The null-model is that the mean expression
levels are the same in both cell types, and the alternativemodel is that themean expression levels are allowed to differ between the two
cell types. Genes with a larger posterior probability for the second model, an RPKM value greater than 2 in any of Mo or Mf and mini-
mally a 2-fold expression change were considered as differentially expressed. Expression changes related to differentiation of each
treatment were studied using a 52-model comparison, a.k.a. polytomous comparison, under the null-model that assumes the mean
expression levels are the same across each time-point. Expression differences related to the treatments at each time-point were stud-
ied using a 5-model comparison, under the null-model that assumes the mean expression levels are the same across each treatment.
ChIP-Seq Data Analysis
Sequencing reads were aligned to human genome assembly hg19 (NCBI version 37) using bwa. Duplicate reads were removed after
the alignment with the Picard tools. For peak calling the BAM files were first filtered to remove the reads with mapping quality less
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than 15, followed by fragment size modeling (https://code.google.com/archive/p/phantompeakqualtools/). MACS2 (https://github.
com/taoliu/MACS/) was used to call the peaks. H3K4me1,H3K9me3 and H3K27me3 peaks were called using the broad setting of
MACS2 while H3K27ac and H3K4me3 were called using the default (narrow) setting. For each histone mark dataset, the data
were normalized using the RpackageDESeq2 and then pair-wise comparisonswere performed (fold change 3, adjusted p-adjvalue <
0.05 and RPKMR 2 in at least in any condition) to determine the differentially expressed genes per condition. The results from all
possible pairwise comparisons (within each condition and similar time points across all conditions per mark) were pooled and
merged to define the dynamic set of enriched regions. Promoters were defined as regions between ± 2kb from TSSs for each
ensemble gene and enhancers were determined as enriched H3K27ac/H3K4me1 regions more than ± 2kb away from the TSS.
To find different patterns over dynamic promoters or enhancers, we applied a K-means clustering procedure (with optimal number
of clusters per each dataset) to the dynamic datasets as described above.
ATAC-Seq Data Analysis
The full ATAC-seq protocol is available at the BLUEPRINT website (http://www.blueprint-epigenome.eu/UserFiles/file/Protocols/
ATAC_Seq_Protocol.pdf). ATAC-seq readsweremapped to the hg19 reference genome using BWA (Li andDurbin, 2009) with default
parameters. Non-uniquely mapped reads and PCR duplicates were removed. MACS2 (Zhang et al., 2008) was used to identify re-
gions of open chromatin (peaks) with parameters ‘‘–nomodel -p 1e-9.’’ Overlap peaks from different samples were merged.
DNA-Binding Motif Scanning
All the DNA-binding motifs used in this study are based on the cis-bp database described in (Weirauch et al., 2014). Only motifs with
direct evidence of binding in the species of vertebrate were selected. Within eachmotif family, as annotated by cis-bp, all motifs were
clustered using ‘gimme cluster’ from the GimmeMotifs package (van Heeringen and Veenstra, 2011) with a threshold of 0.9999. The
annotation of motifs is based on the annotation of human in the cis-bp database. Motifs were used for scanning if the assigned TF is
expressed (> 1 RPKM) in at least one time-point during the differentiation. Total ATAC-seq peaks were scanned for the presence of
motifs. We used Gimme motifs for scanning with dynamic motif scoring cut-offs targeting a false discovery rate (FDR) of both 0.01
and 0.05. To look at the motif enrichments in each set of regions (epigenetic cluster or gene cluster), ATAC-seq peaks were assigned
to the epigenomic cluster or the gene promoters by intersection. Motif occurrences were acquired by intersection of the assigned
ATAC-seq peaks with the motif scanning results on total ATAC-seq peaks. Total ATAC-seq peaks were divided into promoter set
and non-promoter set as the background for the calculation of motif enrichment. Enrichment of motifs in each set of regions was
defined by applying a hypergeometric test using the motif frequency in the corresponding background. This results in TFs that pu-
tatively regulate the activities of the regulatory regions. Motifs in each heat map satisfy an arbitrary cutoff of > 5%motif presence and
a fixed minimal presence difference from background in at least one cluster. Hierarchical clustering (Pearson correlation) was per-
formed in each heat map using the motif occurrence frequencies in the clusters. Based on the gene activity and dynamics, only one
TF was selected to represent a motif if multiple genes are assigned to the same motif. Scanning results from FDR of 0.01 and 0.05
were compared and do not affect the result of enrichment analysis.
Gene Ontology Analysis
Gene ontology analysis on dynamic lists of genes was performed using DAVID (Huang da et al., 2009). Gene ontology on dynamic
enhancer clusters was performed using GREAT (McLean et al., 2010). KEGG pathways and Biological Processes were ranked by p
value and the top terms were plotted.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical parameters including the exact value of n, the definition of center, dispersion, and precision measures (mean ± SEM) and
statistical significance are reported in the Figures and the Figure Legends. Data are judged to be statistically significant when p < 0.05
by two-tailed Student’s T-Test or 2-way ANOVA, where appropriate.
DATA AND SOFTWARE AVAILABILITY
Data Resources
Raw data files for the RNA, ATAC, and ChIP sequencing and analysis have been deposited in the NCBI Gene Expression Omnibus
under accession number: GSE85246.
Links to GEO SubSeries linked to GSE85246:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85243
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85245
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE87218
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Figure S1. Summary of DynamicHistoneMarks and PCAPlots of Dynamic Active HistoneModifications at Promoters andRepressiveMarks,
Related to Figure 1
(A) Percentage of histone ChIP-seq peaks designated as dynamic across time-points and between treatments. H3K27ac was the most dynamic modification,
with almost a third of regions showing significant changes.
(B) Heatmap showing histone intensity of H3K27ac and H3K4me1 at dynamic H3K27ac enhancers with 12kb ± from center of the peak.
(C) PCA plots for all time-points for H3K27ac dynamic promoters, H3K4me3 dynamic promoters, dynamic H3K27me3 regions, and dynamic H3K9me3 regions.
H3K27ac and H3K4me3 at promoters behave similarly over time and in response to LPS or BG exposure, and reflect the behavior of H3K27ac at enhancers.
Unlike active marks, repressive marks show little dynamics up to day 1.
(D) Stacked plots showing chromatin state changes over differentiation at ‘‘LPS-Mf up’’ and ‘‘BG up / LPS down’’ H3K4me1 enhancers. These enhancers are
established through H3K27ac dynamics shown in Figure 1C. The genome was segmented into 9 chromatin states based on the 5 histone marks analyzed. This
analysis indicates that H3K4me1 increase is associated with loss of H3K27me3.
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Figure S2. RNA-Seq Dynamics in Response to LPS and BG and Relationship to Histone Marks, Related to Figure 1
(A) Number of genes showing treatment (LPS or BG) specific expression at each time point (1h, 4h, d1, d6). LPS exposure induces the largest number of genes at
each time-point, with a minimum of 110 transcripts at 1h, and a maximum of 650 transcripts at day 1. Up to 100 genes maintain LPS-specific expression at d6.
Comparatively BG induced gene expression patterns peak at d1, a fraction of which is maintained to d6.
(B) Overlap between gene expression group and promoter H3K27ac cluster. LPS-induced H3K27ac accumulation at promoters correlates well with LPS induced
gene expression at all time-points. However, at day 1 and day 6, the ‘LPS-up’ genes are equally explained by a lag in differentiation-associated repression in LPS
treated cells. Conversely, BG exposure leads to faster expression of differentiation associated genes, with higher overlap between ‘BG-up’ genes and ‘differ-
entiation gain’ and BG-associated H3K27ac promoters.
(C) Example tracks of a BG induced/LPS repressed gene and an LPS induced gene, LPL (Lipoprotein Lipase).
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Figure S3. DNA Methylation Dynamics in Monocyte-to-Macrophage Differentiation and Tolerance and Training, Related to Figure 1
(A) Correlation plot of DNA methylation values, showing clear separation of LPS d1 and LPS-d6 from other samples.
(B) Boxplot of 2,700 DMRs, showing that the general trend is loss of methylation during monocyte-to-macrophage differentiation.
(C) Chromatin context of DMRs. The majority (91%) of DMRs occur in distal regions marked by H3K4me1, 69 occur at H3K27ac marked enhancers and open
chromatin regions. Only 6% occur at promoters.
(D) Boxplots showing DNAmethylation over time for macrophage sub-type specific DMRs. Analysis identified DMRs common to all macrophages, and those that
are only established in LPS-Mf or not-established in LPS-Mf.
(E) Heatmap of H3K27ac changes at DMRs. Generally, DNA de-methylation at DMRs was associated with accumulation of H3K27ac.
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Figure S4. Expression of Transcription Factors with Enriched Motifs at BG-Associated Promoters and Enhancers and Pathways Associated
with Downstream Genes, Related to Figure 2
(A) The expression of main genes enriched at ‘BG up / LPS down’ and ‘Differentiation gain’ promoters and enhancers is shown separately for each donor over
time. Naive cells are green, LPS exposed cells are red, and BG exposed cells are purple. EGR2 expression peaks transiently at 4 hr in BG exposed cells, but by
day 6, there is no difference between Naive, LPS-Mf or BG-Mf.CSF1 andMITF expression peaks at day 1 and then is reduced. Downstream TFUSF2 shares one
motif with MITF, and shows high expression in BG macrophages at day 6. LAMP1 is a major component of the lysosome, and together with LAMP2 makes up
50% of all lysosomal proteins. LAMP1 expression peaks late, and is significantly higher in BG-Mf compared to naive and LPS-Mf. qPCR was used to validate
RNA-seq results in monocytes from multiple donors.
(B) Transcription Factor network based on EGR2 and MITF motif occurrence at BG induced lysosome and lipid metabolism genes. The size of the nodes
represents the number of connections. EGR2 motif is present in the MITF promoters (thick connection). EGR2 and/or MITF motifs are present in another 28 TFs,
which themselves have 14 distinct motifs (and are visible as a cluster. Most genes have a combination of EGR2, MITF and a downstream TF motifs (light brown
circle). The set of genes to the right do not have EGR2 or MITF motifs, but have motifs for one of the downstream TFs (light gray circle). Overall this network
explains 79% of BG-induced lipid metabolism and lysosome-associated genes, compared to 58% based on EGR2 and MITF scan alone. BG induces EGR2
expression, through its receptor, Dectin-1, and higher expression of MITF is observed, as well as its activator cytokine factor CSF1 (see also Figure S4).
Conversely, LPS treatment represses EGR2, CSF1 andMITF. Genes are labeled by time at which their expression peaks in BG exposed cells. EGR2 expression
peaks at 4 hr (brown),MITF and KLF9 at day 1 (gold). The rest of the downstream genes peak at day 1 (gold) or peak at day 6 (green). Connections between TFs
and downstream genes is shown as red lines.
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Figure S5. Tolerance at the Transcriptional Level, Related to Figure 3
(A) Pattern of expression of tolerized and responsive genes during the time-course shown as median logFC of two donors (with first and third quartiles shown as
shaded areas). The most tolerized (G1) genes did not show upregulation in response to the initial LPS exposure in monocytes, while responsive genes (G3)
showed high induction in monocytes.
(B) Notable examples of tolerized and responsive genes. Data are shown as mean RPKM and error bars are standard deviations. Data are represented as
mean ± SD.
(legend continued on next page)
(C) Expression of IL6 and TNF. Release of these proteins frommacrophages in response to LPS is considered the gold-standard for determining tolerance. At the
transcriptional level TNF is partially tolerized, while IL6 is responsive in LPS-Mf. Error bars represent standard deviation. IL6 and TNF protein release after LPS
restimulation is high in BG-Mf and absent in LPS-Mf compared to naive-Mf. The disconnect between transcription and release of IL6 can potentially be explained
by the larger size and higher lysosome content in BG-Mf, induced by early activation of lipid and lysosome pathways in BG exposed cells.
(D) Top 10 KEGG pathways enriched in tolerized and responsive gene groups from DAVID ontology analysis. Area relates to the number of genes within the
pathway, red font signifies that the pathway only shows significant enrichment in the tolerized gene group. Cytokine-cytokine receptor signaling was the top
pathway in both tolerized and responsive groups indicating that cytokine genes are equally spread across the gradient of LPS-Mf response to LPS re-exposure.
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Figure S6. Active Histone Mark Changes at Promoters of Tolerized and Responsive Genes and Overall Chromatin States at the Same
Promoters, Related to Figure 4
(A) Expression at day 6 and at LPS re-exposure for STAT2 and 5A, and IRF1 and 8 (mean RPKM of 4 donors, error bars represent standard deviation). These
pro-inflammatory TFs show a tolerized response in LPS-Mf to LPS re-exposure. The inability of these genes to be activated may play a role in the tolerance of
downstream targets, as suggested from the enrichment of their motifs in the G2 partially tolerized gene promoters (Figure 4B).
(B) expression at day 6 and at LPS re-exposure for NFKB1 and RELA. These TFs are responsive to LPS re-exposure in LPS-Mf, and their motifs are not
significantly enriched in tolerized genes. This suggests that NF-kB signaling is not impaired at the level of transcription. Data are represented as mean ± SD.
(C) LPS-Mf do not accumulate H3K4me3 at tolerized genes, but do so at the promoters of responsive genes. This pattern is similar to that of H3K27ac shown in
Figure 4D.
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Figure S7. Expression of Genes Involved in Lipid Biosynthesis and Metabolism following BG Reversal of LPS-Induced Tolerance, Related to
Figure 7
(A) Experimental set-up, indicating the collection of samples for gene expression analysis. Samples were collected at day 1 +4h, indicating that monocytes were
treated with media (RPMI) or LPS for 24 hr, at which point cells were exposed to BG for 4 hr and collected. Additionally samples were collected at day 3 and day6.
(B) BG exposure, following LPS, recovers the expression of genes involved in lipid biosynthesis and oxidative phosphorylation as early as day 3. LAMP1 is
an example of a lysosome gene that shows high expression in BG-Mf and low expression in LPS-Mf. BG exposure recovers the expression of this gene in
LPS-BG-Mf.
(C) BG addition at day 1 in Naive monocytes induces the expression of EGR2, MITF and CSF1, as it does when added at day 0 (Figure S4C). In tolerized
monocytes, BG induces the expression of EGR2 andMITF, but to a lesser degree. This indicates that BG receptor pathways are not completely disrupted by LPS
exposure, providing a basis for BG reversal of LPS-induced tolerance.
